Abstract 1652
Background
In cancer patients undergoing myelosuppressive chemotherapy, granulocyte colony-stimulating factor (G-CSF) reduces the risk of neutropenic complications and decreases need for dose reductions,1 allowing potential improvement of survival. A recent meta-analysis found that those receiving G-CSF have significantly improved overall survival (OS) versus those who do not.2 Deemed a “gold standard” approach for estimating probabilities of survival for time-to-event data,3 Kaplan-Meier (KM) estimates are a non-parametric method with no underlying distributional assumptions, allowing comparison between studies. Meta-analysis methods based on KM curves have been proposed.4,5 We present a new approach of pooling KM curves, improving their accuracy in assessing survival probabilities.
Methods
Our new approach pinpoints specific coordinates on KM curves using web-based digital graphics data extraction tools. When the amount of at risk patients during a specific time period is known, the number of patients experiencing events can be calculated, or if unknown, imputed by “borrowing” event percentages from a study with a similar KM survival profile. Using minimum squared distances between pairs, the similarity between two KM curves can be determined. Reconstructed event times can be used for meta-analyses, using fixed or random effect modeling with weights for each study.
Results
This approach was applied to 70 reports of OS in cancer patients receiving chemotherapy with or without G-CSF prophylaxis, including recent meta-analysis data.2 Preliminary results are in line with published data. Supporting reports of better survival in patients receiving G-CSF, the new approach provides synthesized KM curves, allowing comparisons of survival probabilities between treatments at any given time points.
Conclusions
Our preliminary results support findings of significantly improved OS in cancer patients receiving G-CSF. References: 1. Aapro et al. Support Care Cancer 2010;18:529–41. 2. Lyman et al. Blood 2017:130;3424. 3. Land et al. Procedia Comput Sci. 2011;6:267–72. 4. Parmar et al. Statist Med. 1998; 17:2815–34. 5. Tierney et al. Trials 2007;8:16.
Clinical trial identification
Legal entity responsible for the study
Hexal AG, Holzkirchen, Germany.
Funding
Hexal AG, Holzkirchen, Germany.
Editorial Acknowledgement
Terri Penfold, Spirit Medical Communications.
Disclosure
A. Krendyukov, L. Yau: Employee: Hexal AG.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract